Consequences of suboptimal glucocorticoid replacement therapy in Addison*s disease; The metabolic syndrome and quality of life.

Withdrawn

• Conditions: Addison's disease; 10001353; primary adrenal insufficiency; 10013317

• Registration Number: NL-OMON32767
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 242

Inclusion Criteria

- primary adrenal insufficiency
- 18-70 years
- stable glucocorticoid replacement therapy (no adjustments of regime and dosage for 3 months)

Exclusion Criteria

- intercurrent infectious or serious disease for which it is necessary to increase
glucocorticoid dosage
- high dose inhalation glucocorticoids (>800 microgram a day)
- pregnancy

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>1) Presence of metabolic syndrome (3 or more abnormalities of waist<br /><br>circumference, blood pressure, triglycerides, HDL<br /><br>cholesterol, glucose)<br /><br>2) Quality of life score</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Presence of glucocorticoid receptor polymorfisms and GRT in relation to the<br /><br>metabolic syndrome and QoL. </p><br>